You can buy or sell PRNB and other stocks, options, ETFs, and crypto commission-free!
Principia Biopharma Inc. Common Stock, also called Principia Biopharma, is a biopharmaceutical company which engages in design and development of small molecule drugs within the fields of autoimmune disease and oncology. Read More It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Markets InsiderMar 2
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids -- -- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of treatment -- -- Complete Response rate of 25 percent with 12 weeks of treatment -- -- Results suggest a favorable risk-benefit profile in pemphigus patients; Principia looks to confirm these results in ongoing Phase 3 PEGASUS study -- SOUTH SAN FRANCISCO, Calif., March 02, 2019 (GLOBE NEWSWIRE) -- Prin...
-$0.31 per share
Available Mar 19, After Hours